DT 200

Drug Profile

DT 200

Alternative Names: DT-200; G 100192; GLPG-0492; SARMs - Galapagos NV

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProSkelia
  • Developer Akashi Therapeutics; Galapagos NV
  • Class Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Duchenne muscular dystrophy
  • Discontinued Cachexia

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (PO)
  • 15 Sep 2014 Preclinical trials in Duchenne muscular dystrophy in USA (PO)
  • 24 Jun 2014 DART Therapeutics is now called Akashi Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top